Yuanyuan Wang

Yuanyuan Wang

Auto-generated profile, based on publicly available information

Yuanyuan Wang

The College of Public Health, Shanghai University of Medicine & Health Sciences, 279 Zhouzhu Road, Pudong New Area, Shanghai 201318, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2023 in Chemosphere
Verified
Journal Article
Closed access
YWYuanyuan Wang
Yuanyuan Wang
XHXinhao Han
Xinhao Han
JLJingkun Li
Jingkun Li
LZLiuchao Zhang
Liuchao Zhang
YLYu Liu
Yu Liu
XCXia Chu
Xia Chu

1 November 2020 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YWYuanyuan Wang
Yuanyuan Wang
ZZZihao Zhou
Zihao Zhou
LCLiang Chen
Liang Chen
YLYuzheng Li
Yuzheng Li
ZZZengyuan Zhou
Zengyuan Zhou
XCXia Chu
Xia Chu

31 October 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
YWYuanyuan Wang
Yuanyuan Wang
XZXue Zhao
Xue Zhao
LZLiuchao Zhang
Liuchao Zhang
CYChunxiao Yang
Chunxiao Yang
KZKening Zhang
Kening Zhang
XCXia Chu
Xia Chu
The etiology of numerous metabolic disorders is characterized by hepatic insulin resistance (IR). Uncertainty surrounds miR-34a’s contribution to high-fat-induced hepatic IR and its probable mechanism. The role and mechanism of miR-34a and its target gene ENO3 in high-fat-induced hepatic IR were explored by overexpressing/suppressing miR-34a and ENO3 levels in in vivo and in vitro experiments. Moreover, as a human hepatic IR model, the miR-34a/ENO3 pathway was validated in patients with non-alcoholic fatty liver disease (NAFLD). The overexpression of hepatic miR-34a lowered insulin signaling and altered glucose metabolism in hepatocytes. In contrast, reducing miR-34a expression significantly reversed hepatic IR indices induced by palmitic acid (PA)/HFD. ENO3 was identified as a direct target gene of miR-34a. Overexpression of ENO3 effectively inhibited high-fat-induced hepatic IR-related indices both in vitro and in vivo. Moreover, the expression patterns of members of the miR-34a/ENO3 pathway in the liver tissues of NAFLD patients was in line with the findings of both cellular and animal studies. A high-fat-induced increase in hepatic miR-34a levels attenuates insulin signaling and impairs glucose metabolism by suppressing the expression of its target gene ENO3, ultimately leading to hepatic IR. The miR-34a/ENO3 pathway may be a potential therapeutic target for hepatic IR and related metabolic diseases.

12 July 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
YWYuanyuan Wang
Yuanyuan Wang
RYRuiming Yang
Ruiming Yang
ZCZiteng Cao
Ziteng Cao
SHSijia Han
Sijia Han
THTianshu Han
Tianshu Han
WWWei Wei
Wei Wei
Hyperuricemia (HUA) is associated with a wide range of diseases and increases the public health burden on society as a whole. In addition to genetic variation, diet plays a crucial role in the prevention and treatment of HUA as an important modifiable behavior. The purpose of this study is to investigate whether food groups and consumption time are associated with HUA. A total of 41,230 participants from the National Health and Nutrition Examination Survey between 2005 and 2018 were included in the study. All meals, including breakfast, lunch, and dinner, were obtained according to their corresponding Food Patterns Equivalents Database dietary data. The binary logistic regression model was used to analyze the relationship between food groups, food consumption time and HUA. We found that the intake of fruit (mixed in various forms) (OR = 0.942, 95% CI: 0.909–0.976) or freshly squeezed juices (OR = 0.915, 95% CI: 0.859–0.975), milk (OR = 0.839, 95% CI: 0.808–0.872), and eggs (OR = 0.881, 95% CI: 0.839–0.924), poultry (OR = 1.055, 95% CI: 1.033–1.077) and seafood high in n-3 fatty acids (OR = 1.068, 95% CI: 0.1.018–1.120) at dinner, eating refined grains at breakfast (OR = 0.954, 95% CI: 0.924–0.985) and dinner (OR = 0.962, 95% CI: 0.944–0.980), eating whole grains (OR = 0.908, 95% CI: 0.845–0.976) at lunch, consuming alcoholic beverages or foods at breakfast (OR = 0.748, 95% CI: 0.564–0.990)/lunch (OR = 1.118, 95% CI: 1.008–1.240)/dinner (OR = 1.127, 95% CI: 1.073–1.185) were associated with HUA. Eating particular meals at particular times of the day was related to a lower risk of HUA.

31 August 2025 in Briefings in Bioinformatics
Verified
Journal Article
Open access
YWYuanyuan Wang
Yuanyuan Wang
LZLiuchao Zhang
Liuchao Zhang
HXHongyu Xie
Hongyu Xie
LWLiuying Wang
Liuying Wang
YWYaru Wang
Yaru Wang
LCLei Cao
Lei Cao
Although programmed death (PD)-1 inhibitors inhibitors have been clinically approved for the treatment of lung adenocarcinoma (LUAD), only a few patients benefit from anti-PD-1 therapy. We developed a semi-supervised biological sparse neural network (sBiosNet) based on transfer learning to fully utilize labeled and unlabeled patient data. The pathways from the Reactome database were used to sparse the sBiosNet and extract associated biological features by integrating patients’ genomic mutations and copy number variation data. We assessed the performance of the sBiosNet against random forest and support vector machine using four cohorts and provided clear interpretations using the DeepLIFT algorithm. The sBiosNet achieved the best prediction with an area under the receiver operating characteristic curve (AUROC) of 0.888 and an area under the precision recall curve (AUPR) of 0.919 for responders versus non-responders on the validation cohort, and AUROC of 0.853 and AUPR of 0.894 on an independent external cohort. The ablation experiments demonstrated that biological sparsification and multi-omics data integration, transfer learning and semi-supervised learning all contributed to improving the sBiosNet’s performance. We further confirmed that genes (such as TP53, FGF3, FGFR4, and EGFR) affected LUAD patients’ response to PD-1 inhibitors by regulating pathways. Meanwhile, the Low-risk LUAD patients identified by the sBiosNet obtained significant longer overall survival and progression-free survival with anti-PD-1 therapy. In conclusion, the sBiosNet accurately predicts the response and survival of patients on anti-PD-1 therapy to reduce unnecessary treatment in non-responders.

27 December 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
YWYuanyuan Wang
Yuanyuan Wang
CQChenyin Qu
Chenyin Qu
QDQiannan Di
Qiannan Di
JZJingyi Zhang
Jingyi Zhang
LNLixin Na
Lixin Na
Background: This study aimed to explore the synergistic hypoglycemic effect and mechanism of 1-deoxynojirimycin (DNJ) in mulberry leaves and theaflavins (TFs) in black tea. Methods: The synergistic inhibition of α-glucosidase and α-amylase by DNJ-TFs was evaluated using enzyme assays and the Chou–Talalay model. Insulin-resistant (IR) HepG2 cells and high-fat diet (HFD)-induced type 2 diabetes mellitus mice were treated with DNJ, TFs, or DNJ-TFs, determining the efficacy of drug combinations by measuring glycolipids and inflammatory factors. Network pharmacology and molecular docking were used to identify key target genes and signaling pathways, and CETSA experiments were used to verify the binding of drugs to targets. Key genes were further verified by immunofluorescence, Western blot, and Real-time PCR. Results: DNJ-TFs synergistically suppressed α-glucosidase (CI = 0.85) and α-amylase (CI = 0.76). In HepG2 cells, DNJ-TFs ameliorated palmitic acid-induced IR by promoting glucose uptake, attenuating lipid accumulation, and regulating glycolipid metabolism. In HFD mice, DNJ-TFs counteracted hyperglycemia, dyslipidemia, systemic inflammation and oxidative stress, elevated HOMA-IR, and hepatic steatosis. Network pharmacology integrated with experimental validation identified PTGS2 and MMP9 as key binding targets of DNJ and TFs. Furthermore, DNJ-TFs could inhibit the increase in liver TNFα protein and the decrease in p-AKT, p-GSKα, p-GSKβ, and GLUT2 protein caused by high fat, both in vivo and in vitro. Conclusions: DNJ and TFs exert synergistic glucose-lowering effects by targeting PTGS2/MMP9 and regulating the TNFα/AKT/GSK3/GLUT2 axis, providing a promising natural therapeutic strategy for diabetes management.